These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24878816)

  • 1. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualized therapy for metastatic colorectal cancer.
    Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
    J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
    Lu W; Wei H; Li M; Wang H; Liu L; Zhang Q; Liu L; Lu S
    Mol Med Rep; 2015 Jul; 12(1):1219-24. PubMed ID: 25815786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 8. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
    Dienstmann R; Tabernero J
    Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

  • 11. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
    Chua W; Moore MM; Charles KA; Clarke SJ
    Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 15. What can molecular pathology offer for optimal decision making?
    Aust DE; Sommer U; Baretton GB
    Ann Oncol; 2012 Sep; 23 Suppl 10():x63-70. PubMed ID: 22987994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
    De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
    Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
    Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
    Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.